Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL3813664

Clc1ccc(CN2CCCCC2)cc1.N

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.96
KDM4E B2RXH2 2/20 0.96
HRH3 Q9Y5N1 4/20 0.78
HRH4 Q9H3N8 1/20 0.69
SIGMAR1 Q99720 1/20 0.64
POLB P06746 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
CYP2D6 P10635 1/20 0.62
CYP2C19 P33261 1/20 0.62
MBTD1 Q05BQ5 1/20 0.59
L3MBTL3 Q96JM7 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
HTT P42858 1/20 0.58
CHRM1 P11229 1/20 0.56
HTR2A P28223 1/20 0.56
MCHR1 Q99705 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1276590 0.98 ALDH1A1 (1.00) ALDH1A1KDM4EHRH3HRH4SIGMAR1
SCHEMBL11227514 0.98 ALDH1A1 (1.00) ALDH1A1KDM4EHRH3HRH4SIGMAR1
Hydrochloric Acid SCHEMBL7405362 0.96 ALDH1A1 (0.96) ALDH1A1KDM4EHRH3HRH4SIGMAR1
SCHEMBL7937990 0.96 ALDH1A1 (0.95) ALDH1A1KDM4EHRH3HRH4SIGMAR1
Hydrochloric Acid SCHEMBL7281619 0.93 ALDH1A1 (0.91) ALDH1A1KDM4EHRH3HRH4SIGMAR1
SCHEMBL11610713 0.92 ALDH1A1 (0.88) ALDH1A1KDM4EHRH3HRH4SIGMAR1
Ammonia Solution, Strong SCHEMBL2924519 0.92 ALDH1A1 (0.81) ALDH1A1KDM4EHRH3HRH4SIGMAR1
SCHEMBL23851111 0.91 ALDH1A1 (0.87) ALDH1A1KDM4EHRH3HRH4SIGMAR1
SCHEMBL4277270 0.89 HRH3 (1.00) ALDH1A1KDM4EHRH3HRH4POLB
Hydrochloric Acid SCHEMBL7468055 0.86 HRH3 (0.95) ALDH1A1KDM4EHRH3HRH4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306141-A1 Novel Compounds ASTRAZENECA AB (SE) 2009-12-10 US disclosed
US-7528156-B2 Compounds ASTRAZENECA AB (SE) 2009-05-05 US disclosed
US-6911458-B2 Compounds ASTRA ZENECA (SE) 2005-06-28 US disclosed
US-20050090494-A1 Novel compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2005-04-28 US disclosed
US-20030162772-A1 Novel compounds ASTRAZENECA AB (SE) 2003-08-28 US disclosed
EP-1299357-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2003-04-09 EP disclosed
WO-2001098273-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306141-A1 Novel Compounds CHRM2, CHRM1, C1R ALDH1A1 1779/4885KDM4E 1451/4885HRH3 491/4885
US-20050090494-A1 Novel compounds CHRM2, CHRM1, C1R ALDH1A1 1779/4885KDM4E 1451/4885HRH3 491/4885
US-20030162772-A1 Novel compounds RPS4X, RPS4Y1, MRPS18A ALDH1A1 949/4885KDM4E 1288/4885HRH3 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.